Encompass More Asset Management Takes $386,000 Position in Eli Lilly and Company (NYSE:LLY)

Encompass More Asset Management purchased a new position in Eli Lilly and Company (NYSE:LLY) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 436 shares of the company’s stock, valued at approximately $386,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of LLY. Acropolis Investment Management LLC grew its position in shares of Eli Lilly and Company by 2.9% in the 3rd quarter. Acropolis Investment Management LLC now owns 1,666 shares of the company’s stock worth $1,476,000 after acquiring an additional 47 shares in the last quarter. L.M. Kohn & Company increased its stake in Eli Lilly and Company by 13.4% during the third quarter. L.M. Kohn & Company now owns 2,725 shares of the company’s stock valued at $2,414,000 after purchasing an additional 323 shares during the last quarter. Kolinsky Wealth Management LLC raised its holdings in shares of Eli Lilly and Company by 20.4% during the third quarter. Kolinsky Wealth Management LLC now owns 425 shares of the company’s stock worth $377,000 after purchasing an additional 72 shares during the period. Eventide Asset Management LLC lifted its position in shares of Eli Lilly and Company by 249.2% in the 3rd quarter. Eventide Asset Management LLC now owns 4,128 shares of the company’s stock worth $3,657,000 after buying an additional 2,946 shares during the last quarter. Finally, CWS Financial Advisors LLC grew its position in shares of Eli Lilly and Company by 7.3% during the 3rd quarter. CWS Financial Advisors LLC now owns 1,200 shares of the company’s stock valued at $1,063,000 after buying an additional 82 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $795.35 on Friday. The firm has a market cap of $755.04 billion, a PE ratio of 85.98, a price-to-earnings-growth ratio of 2.99 and a beta of 0.43. The company’s 50-day moving average price is $851.90 and its two-hundred day moving average price is $869.52. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a 12 month low of $561.65 and a 12 month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The firm had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. During the same quarter in the prior year, the company earned $0.10 EPS. Eli Lilly and Company’s quarterly revenue was up 20.4% on a year-over-year basis. On average, equities analysts anticipate that Eli Lilly and Company will post 13.2 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 annualized dividend and a yield of 0.65%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 56.22%.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on LLY shares. Barclays reduced their price objective on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a report on Thursday, October 31st. Bank of America decreased their price target on Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating for the company in a research note on Thursday, October 31st. Redburn Atlantic upgraded Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Deutsche Bank Aktiengesellschaft lowered their target price on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Finally, Wolfe Research started coverage on shares of Eli Lilly and Company in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price objective on the stock. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,007.94.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction on Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the sale, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.